EBV vaccine expected to be cost-effective in preventing MS: Study
Researchers looked at giving vaccination at birth and age 12
Using a vaccine against the Epstein-Barr virus (EBV) to prevent the development of multiple sclerosis (MS) is highly likely to be cost-effective, especially when given in early adolescence, according to an Australian modeling study.
“The evidence from this study highlights the urgent need for the development of an EBV vaccine, and it identifies a potentially preferential vaccination strategy targeting young adolescents,” the researchers wrote.
The modeling study, “Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting,” was published in the Journal of Neurology, Neurosurgery and Psychiatry.
https://multiplesclerosisnewstoday.c...ing-ms/
Researchers looked at giving vaccination at birth and age 12
Using a vaccine against the Epstein-Barr virus (EBV) to prevent the development of multiple sclerosis (MS) is highly likely to be cost-effective, especially when given in early adolescence, according to an Australian modeling study.
“The evidence from this study highlights the urgent need for the development of an EBV vaccine, and it identifies a potentially preferential vaccination strategy targeting young adolescents,” the researchers wrote.
The modeling study, “Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting,” was published in the Journal of Neurology, Neurosurgery and Psychiatry.
https://multiplesclerosisnewstoday.c...ing-ms/